阿尔茨海默氏病中的谷氨基质系统:通过元分析进行系统性审查
Carolina Soares1,2, Lucas Uglione Da Ros1, Luiza Santos Machado1
1Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Molecular psychiatry
|February 17, 2024
概括
阿尔茨海默氏病 (AD) 的大脑显示了谷氨酸和酸盐水平的降低,以及谷氨酸的再吸收受损和N-甲基-D-酸盐受体功能的改变. 这些发现突显了AD病理生理学中的谷氨基质体系统缺陷.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理生理学 病理生理学
背景情况:
- 谷氨酸性神经传递对大脑功能至关重要.
- 这个系统的失调与阿尔茨海默病 (AD) 病理生理学有关.
- 此前对阿尔茨海默氏症大脑中的谷氨基基成分的研究产生了矛盾的结果.
研究的目的:
- 系统地审查和对现有文献进行元分析,以确定人类AD大脑中一致的谷氨基质异常.
- 在不同大脑区域中对各种谷氨基基成分 (如谷氨基酸,谷氨基胺,载体,受体) 的发现进行合成.
主要方法:
- 在PubMed和Web of Science数据库中进行系统搜索 (截至2023年10月).
- 包括评估人类AD大脑中的谷氨酸标记物的研究,重点关注皮质区域,整个大脑,内腔皮质和海马.
- 使用标准化平均差异 (SMD) 随机效应的元分析,调整为错误发现率和异质性评估 (I2统计).
主要成果:
- 分析显示,AD大脑中的谷氨酸 (SMD = -0.82) 和酸盐 (SMD = -0.64) 水平下降.
- 观察到谷氨酸再吸收 (SMD = -0.75),AMPA受体亚单元水平 (GluA2 / 3,SMD = -0.63) 和N-甲基-D-亚斯巴酸受体 (NMDAR) 低功能的显著降低 (SMD = -0.60).
- 具体的区域性下降包括皮质区域中的谷氨酸,皮质区域和海马体中的酸盐,以及体内皮质和海马体中的NMDAR-GluN2B亚单元水平.
结论:
- 人类AD大脑表现出一个耗尽的谷氨基基质系统,其特征是神经递质水平降低和受体功能受损.
- 这些发现强调了谷氨酸中介的神经毒性在AD病变发生过程中的重要性.
- 了解这些谷氨酸基质变化对于开发新的AD疗法和生物标志物至关重要.
相关概念视频
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
01:26Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
01:14Antiepileptic Drugs: Glutamate Antagonists
355
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
355